BioXcel Therapeutics (BTAI) Accounts Payables (2017 - 2026)

BioXcel Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $16.2 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 5.16% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at $16.2 million (up 5.16% YoY), while the FY2025 annual figure was $14.7 million, down 8.06% from the prior year.
• Accounts Payables was $16.2 million for Q1 2026 at BioXcel Therapeutics, up from $14.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $17.2 million in Q1 2024 to a low of $5.1 million in Q1 2022.
• Historically, Accounts Payables has averaged $12.4 million across 5 years, with a median of $13.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 141.13% in 2022, then dropped 10.28% in 2025.
• A 5-year view of Accounts Payables shows it stood at $10.2 million in 2022, then jumped by 33.5% to $13.7 million in 2023, then rose by 17.11% to $16.0 million in 2024, then dropped by 8.06% to $14.7 million in 2025, then advanced by 10.52% to $16.2 million in 2026.
• The last three Accounts Payables figures came in at $16.2 million (Q1 2026), $14.7 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.